The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers.
This article was originally published on MedicalXpress.com
GLP-1 drug shows little benefit for people with Parkinson’s disease, trial finds
You may also be interested in:
The Latest
Will a nutritional supplement help you run better?
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
The Latest
Microneedling Services in Edmonton: Benefits, Treatment Cost, and How It Works
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
The Latest
PetVet Dx Revolutionizes Wildlife Conservation with AI and Molecular Diagnostics to Combat Incurable CWD in Deer and Elk
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
Read More:
-
Learning French while also developing language skills in one’s mother tongue is no easy task. As a result, allophone children often face learning and communication [...]
-
People who develop multiple sclerosis (MS) as children and grow up in less advantaged neighborhoods may have a larger volume of inflammation and brain tissue [...]
-
Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6, according to a long-running study. The [...]
